Oxizol1%

Oxizol is a topical imidazole antifungal indicated for:

• FDA-approved uses: Treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm) caused by susceptible dermatophyte organisms, in patients 12 years of age and older.
• FDA-approved use (cream formulation): Treatment of cutaneous candidiasis caused by susceptible Candida species.
• FDA-approved use (lotion formulation): Treatment of tinea (pityriasis) versicolor caused by Malassezia furfur.

Oxizol is functionally equivalent in clinical use to oxiconazole base, being its nitrate salt form. It is intended for external/topical use only and is not established as a treatment for nail (onychomycosis) or scalp fungal infections. There are no well-established off-label uses that warrant routine mention.

Each gram of Oxiconazole Nitrate topical cream or lotion typically contains oxiconazole nitrate equivalent to 1% w/w oxiconazole base, in a suitable topical vehicle base. Exact strength, formulation (cream or lotion), and excipients may vary by manufacturer/brand; refer to the specific product packaging/leaflet for complete details.

Oxizol is the nitrate salt form of oxiconazole, a synthetic imidazole-derivative antifungal agent for topical use. It is active against a range of dermatophytes and yeasts responsible for common superficial fungal skin infections. Oxizol is available as a topical cream (also used for cutaneous candidiasis) and a topical lotion (also used for tinea versicolor).

Oxizol belongs to the imidazole class of antifungal agents, used topically for the treatment of superficial dermatophyte and yeast infections of the skin.

Oxiconazole Nitrate exerts its antifungal effect by inhibiting the fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase, which is required for the conversion of lanosterol to ergosterol, the principal sterol of the fungal cell membrane. Depletion of ergosterol and accumulation of toxic sterol intermediates disrupt the structure and function of the fungal cell membrane, leading to increased membrane permeability, leakage of cellular contents, and inhibition of fungal growth. Oxiconazole Nitrate is fungistatic against dermatophytes such as Trichophyton, Epidermophyton, and Microsporum species, and is active against Candida species and Malassezia furfur. Following topical application, systemic absorption of Oxiconazole Nitrate is minimal.

Wash and dry hands before and after application. Gently cleanse and dry the affected skin area. Apply a thin layer of Oxizol to cover the affected area and immediate surrounding skin, and rub in gently. Avoid contact with the eyes, mouth, nose, and other mucous membranes. Do not apply an occlusive dressing over the treated area unless directed by a physician. Oxizol is intended for external use only and must not be swallowed.

Because Oxizol is applied topically with minimal systemic absorption, clinically significant systemic drug interactions have not been well established. No specific well-verified interactions with other topical or systemic medications requiring dose adjustment are documented. Avoid simultaneous application of other topical products (e.g., other topical corticosteroids or antifungals) on the same skin area unless advised by a physician, as this may affect drug penetration or local skin tolerance. Inform your physician or pharmacist of all other medicines and topical products being used.

Oxizol is generally well tolerated when used as directed. The most commonly reported side effects are local skin reactions at the application site, including:

• Burning or stinging sensation
• Itching
• Redness (erythema)
• Skin irritation or dryness

These effects are usually mild and transient. Less commonly, more pronounced local reactions such as blistering, peeling, or contact dermatitis may occur. If severe irritation, signs of an allergic reaction, or worsening of the skin condition develop, discontinue use and consult a physician.

There are no adequate and well-controlled studies of Oxizol in pregnant women. Because systemic absorption after topical application is minimal, the risk to a developing fetus is expected to be low, but Oxizol should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use. It is not known whether topically applied Oxizol is excreted in human breast milk in clinically significant amounts. Caution should be exercised when Oxizol is used by a breastfeeding woman, and application directly on or near the breast/nipple area should be avoided to prevent inadvertent ingestion by the infant; consult a physician.

Oxizol is for external/topical use only and must not come into contact with the eyes, mouth, or other mucous membranes; if accidental contact occurs, rinse thoroughly with water.

• Local irritation: Burning, stinging, or irritation can occur at the application site (see Side Effects); discontinue if severe irritation or sensitization develops.
• Complete the full course: Complete the full recommended treatment course even if symptoms improve early, to reduce the risk of recurrence.
• Lack of response: Seek medical evaluation if there is no improvement after the labeled treatment duration, or if symptoms worsen, as this may indicate an incorrect diagnosis or a resistant organism.
• Not for internal, ophthalmic, or vaginal use.

Topical overdose with Oxizol is unlikely to cause systemic toxicity given its minimal systemic absorption; excessive application may increase the likelihood of local skin irritation. If Oxizol is accidentally ingested, or if accidental contact with the eyes occurs with persistent irritation, seek immediate medical attention or contact a poison control center/emergency services.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal and hepatic impairment: No dose adjustment is required for Oxizol in renal or hepatic impairment, given its topical route of administration and minimal systemic absorption.

Elderly: No specific dose adjustment is required for elderly patients; general precautions for topical use apply.

Pediatric patients: See Pediatric Uses.

Treatment duration with Oxizol depends on the indication and formulation: typically 2 weeks for tinea cruris, tinea corporis, cutaneous candidiasis, and tinea versicolor, and 2 to 4 weeks for tinea pedis. The full recommended course should be completed as directed even if symptoms improve early. If no improvement is seen after the labeled duration, or if symptoms worsen, medical evaluation should be sought.

Oxiconazole Nitrate belongs to the imidazole antifungal drug class, used topically for dermatophyte and yeast skin infections.

Oxiconazole Nitrate inhibits the fungal enzyme lanosterol 14α-demethylase, blocking conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This depletes ergosterol and causes accumulation of toxic sterol precursors, disrupting fungal cell membrane integrity, increasing permeability, and ultimately inhibiting fungal cell growth and replication.

The safety and efficacy of Oxizol cream and lotion have been established in pediatric patients 12 years of age and older for the approved topical indications. Safety and efficacy in pediatric patients below 12 years of age have not been established. Oxizol should be used in younger children only under medical supervision if a physician determines the potential benefit justifies use.